version: 3
domain: quarterly_reporting
created_by: fnefh
document_outline: >
  This document contains quarterly financial reports (Form 10-Q)
  for Replimune Group, Inc. covering quarters from  2023-2024.

  The reports include detailed information about:

  1. Financial Performance
     - Quarterly operating expenses
     - R&D investments
     - Cash position and runway
     - Operating losses and financing activities

  2. Business Operations
     - Clinical trial progress
     - Pipeline development
     - Manufacturing capabilities
     - Research and development activities

  3. Market Position
     - Clinical milestones
     - Program advancement
     - Strategic initiatives
     - Growth execution

  4. Risk Management
     - Clinical development risks
     - Operational challenges
     - Financial requirements
     - Market conditions
seed_examples:
  - context: >
      In Q3 2024, Replimune reported R&D expenses of $43.4M and total
      operating expenses of $58.9M. The company maintained a strong cash
      position with $432M in cash and investments. Clinical development
      continued across multiple programs, with significant progress in the RP1
      and RP2 trials. The company raised additional capital through a private
      placement and issuance of prefunded warrants.
    questions_and_answers:
      - question: |
          How did Replimune's financial performance evolve in Q3 2024?
        answer: >
          In Q3 2024, Replimune reported R&D expenses of $43.4M and total
          operating expenses of $58.9M, while maintaining a strong financial
          position with $432M in cash and investments, supplemented by
          successful capital raising through private placement and prefunded
          warrants.
      - question: |
          What were the key operational developments during the quarter?
        answer: >
          The company continued advancing its clinical programs, particularly the
          RP1 and RP2 trials, while managing operating expenses and
          strengthening its financial position through strategic financing
          activities.
      - question: >
          How did the company's capital raising activities support its strategic
          objectives?
        answer: >
          The successful private placement and issuance of prefunded warrants
          strengthened Replimune's cash position, providing additional resources
          to support ongoing clinical development programs and operational
          activities.
  - context: >
      In Q2 2024, Replimune focused on advancing its clinical programs while
      managing R&D expenses of $43.0M and total operating expenses of $57.4M.
      The company maintained progress in its RP1 melanoma program and RP2 uveal
      melanoma studies, while preparing for potential regulatory submissions.
    questions_and_answers:
      - question: |
          What were the key financial metrics for Q2 2024?
        answer: >
          In Q2 2024, Replimune reported R&D expenses of $43.0M and total
          operating expenses of $57.4M, demonstrating continued investment in
          clinical development while maintaining financial discipline.
      - question: |
          How did the clinical programs progress during the quarter?
        answer: >
          The company advanced its key clinical programs, including the RP1
          melanoma program and RP2 uveal melanoma studies, while preparing for
          potential regulatory submissions and maintaining development momentum.
      - question: |
          What strategic priorities were evident in the quarter's activities?
        answer: >
          The company focused on advancing its lead clinical programs toward
          potential regulatory submissions while managing expenses and
          maintaining operational efficiency in preparation for future
          milestones.
  - context: >
      In Q3 2023, Replimune reported R&D expenses of $49.1M and total
      operating expenses of $63.8M. The company advanced its clinical trials
      while maintaining a strong cash position. Key developments included
      progress in the IGNYTE and ARTACUS trials, along with continued
      development of manufacturing capabilities.
    questions_and_answers:
      - question: >
          How did Replimune's financial and operational metrics compare in Q3
          2023?
        answer: >
          In Q3 2023, Replimune reported R&D expenses of $49.1M and total
          operating expenses of $63.8M, while advancing its clinical programs
          and maintaining its manufacturing infrastructure development.
      - question: |
          What progress was made in clinical development during Q3 2023?
        answer: >
          The company advanced its IGNYTE and ARTACUS clinical trials while
          continuing to develop its manufacturing capabilities, demonstrating
          progress across both clinical and operational objectives.
      - question: >
          How did the company balance clinical development with operational
          investments?
        answer: >
          Replimune maintained a balanced approach between advancing clinical
          trials and developing manufacturing capabilities, while managing
          operating expenses to support long-term growth objectives.
document:
  repo: https://github.com/fnefh/taxonomy
  commit: 64435d1ca0c755f507949525c9739a4edc4113fe
  patterns:
    - knowledge/finance/financial_reporting/sectors/biotechnology/REPL/10-Q/data/*.md
